- Home
- BDRX vs CVKD Comparison
BDRX vs CVKD Comparison
Compare BDRX & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDRX | CVKD |
|---|---|---|
| Founded | 2000 | 2022 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 17.3M |
| IPO Year | 2015 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BDRX | CVKD |
|---|---|---|
| Price | $0.67 | $5.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 63.3K | 52.2K |
| Earning Date | 09-12-2025 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $4.91 |
| 52 Week High | $11.88 | $19.03 |
Technical Indicators
Market Signals| Indicator | BDRX | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 24.34 | 32.72 |
| Support Level | N/A | $5.13 |
| Resistance Level | $1.29 | $8.87 |
| Average True Range (ATR) | 0.07 | 0.56 |
| MACD | 0.02 | -0.24 |
| Stochastic Oscillator | 6.95 | 0.00 |
Price Performance
Historical ComparisonAbout BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.